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The cellular prion protein (PrPc) is a glycolipid-anchored cell surface protein that usually exhibits three
glycosylation states. Its post-translationally modiﬁed isoform, PrPsc, is involved in the pathogenesis of
various transmissible spongiform encephalopathies (TSEs). In bovine species, BSE infectivity appears
to be restricted to the central nervous system; few or no detectable infectivity is found in lymphoid
tissues in contrast to scrapie or variant CJD. Since expression of PrPc is a prerequisite for prion
replication, we have investigated PrPc expression by bovine immune cells. Lymphocytes from blood
and ﬁve different lymph organs were isolated from the same animal to assess intra- and interindividual
variability of PrPc expression, considering six individuals. As shown by ﬂow cytometry, this expression
is absent or weak on granulocytes but is measurable on monocytes, B and T cells from blood and lymph
organs. The activation of the bovine cells produces an upregulation of PrPc. The results of our in vitro
study of PrPc biosynthesis are consistent with previous studies in other species. Interestingly, western
blotting experiments showed only one form of the protein, the diglycosylated band. We propose that the
glycosylation state could explain the lack of infectivity of the bovine immune cells.
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INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) are
neurodegenerative diseases including bovine spongiform
encephalopathy (BSE), scrapie, Creutzfeldt-Jakob disease
(CJD) and variant (vCJD), fatal familial insomnia,
Gerstmann-Stra ¨ussler-Scheinker’s syndrome and Kuru.
The principal marker of those illnesses is a protein called
PrPsc; its core (PrPres) resists to treatment with proteases
such as proteinase K (Prusiner, 1982). The cellular form of
the prion protein (PrPc) is currently thought to be the
substrate for the synthesis of its pathogenic counterpart
(Bueler et al., 1993). PrPc is encoded in the genome of all
mammalsinvestigatedtodateandseemstohaveanessential
but not yet deﬁned function as shown by a high degree of
evolutionary conservation (Krakauer et al.,1 9 9 8 ) .I nt h e
central nervous system, PrPc expression is very high and
correlates with an important accumulation of infectivity in
the TSEs (Wells et al., 1994). In comparison, all the other
organs have a much lower expression of PrPc (Fournier,
2001). Upon peripheral administration of the agent,
accumulation and/or replication of the prion particles
is ﬁrst found in the spleen (McBride et al., 1992).
Different cells of the immune system appear implicated
in the pathogenesis: lymphocytes, Follicular dendritic
cells (FDCs), macrophages and dendritic cells
(Klein et al., 1997; Brandner et al.,1 9 9 9 ;B r o w net al.,
1999; Montrasio et al., 2000; Beringue et al., 2000; Huang
etal., 2002). FDCs could act askey players,B lymphocytes
and other immune cells having an indirect role as shown by
the different studies using immunodeﬁcient mice (Klein
etal.,1998),orknock-outmiceforthelymphotoxinorTNF
pathways (Mabbott et al., 2000;2002; Prinz et al.,2 0 0 2 ) .
BSE epidemy and the concomitant emergence of the
variant of the CJD in humans (vCJD) raised different
questions. In fact, the numerous common features between
both agents made inter-species transmission of BSE to
human being considered as possible (Collinge, 1997; Scott
et al., 1999). Tissue infectivity in BSE has thus been
comprehensively investigated in cattle with natural or
experimental BSE (Mohri et al.,1 9 9 2 ;S o m e r v i l l eet al.,
1997; Wells et al.,1 9 9 8 ;P a m m e ret al., 1999; Bradley,
1999; Race et al., 2000). In the case of the BSE, several
researches reported lack of accumulation of the infectious
agent within the lymphoid organs, excepted the Peyer’s
patchesofthedistalileum(Wellsetal.,1994;Farquharetal.,
1996; Wells et al., 1998). This peculiarity of the bovine
immunesystemisintriguing.AsPrPcisthesubstrateforthe
development of infectivity, different level of expression
couldaffecttheinfectionandthepropagationofthedisease.
However, knowledge about the expression of PrPc by the
differentlymphoidpopulationsindifferentorgansislimited.
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Developmental Immunology, December 2002 Vol. 9 (4), pp. 245–252In this work, we report the investigation of the PrPc
expression at the surface of bovine lymphoid cells by ﬂow
cytometry. Cytoplasmic and surface content in PrPc of
bovinelymphocytesaswellastheirisoformdistributionwere
thendeterminedbywesternblotting.Wealsostudiedinvitro
the modulation of PrPc expression, reﬂecting biosynthesis
under different in vivo conditions: enzymatic treatment,
stimulation with mitogens and blockade of glycosylation.
MATERIALS AND METHODS
Materials
Blood, palatine tonsils, spleens, Peyer’s patches, thymus
and lymph nodes were obtained at a local abattoir from
clinically healthy 18 months old cattle. Organs were
placed in phosphate buffer saline (PBS) and kept at 48C
until they were processed for isolation of lymphoid cells.
Special attention was dedicated to collect the blood and
organs from the same individual in order to assess the
inter- and intra- individual variability of PrPc expression.
All reagents were of analytical grade and were acquired
from Sigma (Belgium) unless speciﬁcally mentioned.
Antibodies against bovine lymphoid subpopulations were
purchased from Serotec, UK.
AntibodiesagainstPrP(SAF34,12F10ataconcentration
of 1mg/ml) were obtained from Dr J. Grassi, CEA, France.
SAF34 antibody was produced by the team of Dr J. Grassi
against AA79-92 whereas 12F10 antibody was raised
against AA142-160 by the team of Dr Gerhard Hunsmann.
Isolation of Peripheral Blood Mononuclear Cells
Lymphoid cells from complete peripheral blood were
separated by density centrifugation on Ficoll-Paque
(Amersham Pharmacia, Sweden). Lymphocytes and
monocytes were recovered from the interphase, washed
four times with PBS and then resuspended in RPMI 1640
(Bio-Whittaker, Belgium).
The granulocytes were recovered after complete blood
was submitted to red blood cells lysis with water.
Isolation of Tonsil, Spleen, Peyer’s Patch, Thymus and
Lymph Node Lymphocytes
The different bovine organs were cut into fragments,
disrupted and ﬁltered through a 150mm nylon ﬁlter to
eliminateaggregatesandmembranefragments.Theﬁltrate
containing lymphoid cells was separated by density
centrifugation on Ficoll-Paque. Lymphocytes and mono-
cytes were recovered from the interphase, washed four
times and then resuspended in RPMI 1640.
Analysis of PrPc Expression by Flow Cytometry
SAF34 or 12F10 mouse Mab recognizing distinct prion
protein regions were used in indirect labeling experiments.
Different lymphocyte subpopulations are discriminated by
a staining with CD4, CD8 or CD21 speciﬁc Mab.
Brieﬂy, 10
6 cells were ﬁrst incubated in PBS for 30min
at 48C with FITC-coupled antibodies (CD4 or CD8 1/500)
or with antibody against CD21 (1/200) followed by FITC-
coupled rabbit anti-mouse Ig (Dako, Denmark 1/1000).
The cells were washed, and then incubated for another
30min in PBS with biotinylated SAF34 or 12F10 mouse
Mab (diluted 1/1000), washed, incubated for 30min in
PBS with PE-conjugated streptavidin (diluted 1/2000,
Becton-Dickinson, California) and ﬁnally rinsed
before analysis with a FACScalibur (Becton-Dickinson,
California). Cells incubated without speciﬁc MAbs were
used as negative controls. The regions containing
lymphocytes, monocytes and granulocytes were discrimi-
nated on the basis of the cell size (FSC) and granularity
(SSC) showed on the dotplot. The region containing the
lymphocytes was then further investigated on a dotplot of
the ﬂuorescent signals: FL1 represents the labeling of each
subpopulation, the staining of the prion protein is reported
onto the FL2 axis. Quadrant statistics were given by the
Cell Quest program. The results are expressed as the
percentage of double-positive cells within each cell
subpopulation.
Cell Cultures
For all experiments lymphoid cells were grown in RPMI
1640 supplemented with 10% FCS, 2mM L-glutamine,
100mg/ml penicillin and streptomycin. In every condition,
cells were counted and their viability was assessed by
trypan blue exclusion test with a survival of approximately
95–98%.
In order to test the role of the activation status on the
PrPc expression of the cells, the lymphocytes from spleen
or mesenteric lymph nodes were incubated either with or
without different mitogens as L-phytohaemagglutinin
(PHA-L; 1or 2mg/ml), or phorbol myristate acetate (5or
10ng/ml) and ionomycin (0.5 or 1mg/ml) (PMA-iono)
during 6, 24 or 48h at 378C with 5% CO2. The efﬁciency
of the treatment was monitored by
3H thymidine (T
3H)
incorporation as in Takeda et al. (1996) to measure
proliferative responses of mononucleated cells.
Digestion of PrPc at the Cell Surface
We have treated the freshly isolated cells with an
enzymatic cocktail containing 1mg/ml collagenase A,
0.5mg/ml dispase type II, 0.04mg/ml DNase type I
(Boerhinger-Mannheim, Germany) in RPMI 1640 with
0.4% BSA during 1h at 378C. The efﬁciency of the
digestion of PrPc from the cell surface was monitored by
cytometric analysis after labeling with the SAF34 Mab.
Blockade of Glycosylation
To analyze the capacity of the cells to display the
unglycosylated protein at the surface of the membrane,
F. ME ´LOT et al. 246we stopped the protein glycosylation process. Cells were
thus incubated with tunicamycin after the enzymatic
digestion. The incubation was realized either with or
without tunicamycin at a ﬁnal concentration of 1, 2 or
5mg/ml, during 18h at 378C with 5% CO2.
Analysis of PrPc by Western Blotting
Immediately after isolation or culture, the cells were
quickly processed for the SDS-Page and the samples were
frozen at 2208C. Brieﬂy, 10
6 cells were peletted,
resuspended in 20ml of Tris migration buffer (containing
120mM Tris–HCl, 60mM sucrose, 70mM sodium
dodecylsulfate, 0.15mM bromophenol blue, 0.5%
2-mercaptoethanol and 1% Triton X-100 pH 6.8), passed
ﬁve times trough a 22 1/4 gauge-needle and boiled during
2min. The brain sample was prepared by homogeneizing
100mg of tissue into 1ml of buffer (Tris/HCl 10mM
pH 7.4, 100mM NaCl, 10mM EDTA, 0.5% NP-40, 1%
sodium deoxycholate). After centrifugation (10min,
2500g), the supernatant was diluted 1/2 in 2 times
concentrated Tris migration buffer. The cell or tissue
homogenates were subjected to SDS-Page 12%. Proteins
were transferred to a nitrocellulose membrane (Millipore,
Bedford, USA) by electroblotting in a transblot (BioRad,
USA) transfer apparatus for 1h at room temperature.
Before the transfer, the gels, Whatman ﬁlter papers, and
nitrocellulose membrane, were soaked in electroblotting
buffer (25mM Tris–HCl; 192mM glycine; 20% metha-
nol, pH 8.0) for 15min. After transfer, the membrane was
blocked using tris buffer saline (TBS) with 5% dry milk
overnight at 48C. The prion protein was detected by
incubating the membrane for 1h at room temperature with
mouse monoclonal antibody against prion (SAF 34)
diluted 1:500. The membrane was washed three times in
TBS with 0.1% Tween 20 (TBST). Speciﬁc protein was
detected using a horseradish peroxidase-conjugated
secondary antibody and enhanced chemiluminescence
(ECL) reagents (Amersham, UK). Image analysis device
was a ScanJet II scanner with DeskScan II software
(Hewlett Packard, Palo Alto, CA, USA).
RESULTS
Flow Cytometry Analyses of PrPc Expression on
Lymphocytes
We ﬁrst analyzed the PrPc labeling in blood samples.
Monocytes and lymphocytes expressed the PrPc at their
surface while granulocytes were globally negative for the
PrPc immunolabeling (Table I).
The staining of surface PrPc was then realized in
parallel on freshly isolated blood, spleen, tonsils, Peyer’s
patches, thymus and lymph nodes cells. These results were
analyzed for six animals. Figure 1 shows the percentage of
PrPc positive cells in each subpopulation: CD4 (panel a),
CD8 (panel b) and CD21 (panel c). If we consider
the same organ, approximately the same levels of cell
surface staining were observed respectively for each cell
population with the two PrP-speciﬁc antibodies (12F10
gives slightly minor values, data not shown).
TABLE I Expression of PrPc on freshly isolated blood mononuclear
cells (as a percentage of total cell population): cytoﬂuorimetric analysis
with the SAF34 Mab. n ¼ 6
Blood cell population Granulocytes Monocytes Lymphocytes
Percentage of
PrPc expression
0.8 ^ 0.7% 31.8 ^ 3.4% 63.2 ^ 7.6%
FIGURE 1 Expression of PrPc on the bovine lymphoreticular system
cells (as a percentage of total cell population): cytoﬂuorimetric analysis
on freshly isolated mononuclear cells subpopulations from blood
(B), spleen (S), tonsils (To), thymus (Th), Peyer’s patches (PP) and
mesenteric lymph nodes (MLN) with the SAF34 Mab. n ¼ 6:
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or blood T lymphocytes was consistently more important
than on spleen lymphocytes while it is intermediate on the
lymph nodes, tonsils and Peyer’s patches lymphocytes.
This situation appears less marked in the case of the B
cells. For those cells the mean labeling percentages are a
little higher, specially in the case of the tonsils.
An important variability in the percentage of positively
stained splenic cells was noticed reﬂecting important
interindividual variations in prion protein expression.
The staining intensities were also reduced within the
spleen (data not shown).
Effect of Activation on PrPc Level
In order to test the inﬂuence of activation, spleen and
lymph node lymphocytes were maintained in culture
conditions with or without mitogens. We showed that
bovine splenic and mesenteric lymph node lymphocytes
are able to express high quantities of PrPc at their surface
in culture conditions even without stimulation (Fig. 2 (b)).
An increase in [
3H] thymidine incorporation, reﬂecting the
DNA synthesis due to cell proliferation, was seen after 6,
24 or 48h of treatment with PHA or PMA/ionomycin.
High stimulation was obtained after 48h of treatment
with PMA/ionomycin. A representative histogram out of
three experiments is shown on Fig. 2 (b). Cultured splenic
lymphocytes demonstrated an increased cell volume
(Fig. 2(a)) and a higher PrPc expression (Fig. 2 (b)). The
lymphocytes from the mesenteric lymph nodes showed a
minor increase of the PrPc staining (data not shown).
Cleavage of Cell Surface PrPc
A 1h digestion with an enzymatic cocktail containing
collagenase-dispase-DNase abolished the surface PrPc
labeling monitored by FACS analysis. Reexpression of the
membrane protein in vitro was observed when digestion
was followed by a short-term culture. After 6h of culture,
we detected a slight increase of the signal in treated cells
(Fig. 3 (a) and (b)). After 18h of culture, the PrP was
totally reexpressed at the surface of the membrane by the
treated cells.
PrPc Western Blotting
For all immune cells, western blotting with the SAF34
Mab (Fig. 4) revealed only one form of PrPc. The unique
band within all the lymph organs was located at the same
molecular weight as the diglycosylated band from the
brain (34kDa). The brain isoforms were located at 29, 31
and 34kDa. A small isoform was found in the spleen and
blood, and had a molecular weight of 19kDa, certainly
corresponding to a truncated form.
FIGURE2 Comparativedotplots ofspleniclymphocytes directlyafterisolationand48hofculturewithmitogen(a). Histograms ofPrPcexpressionby
spleen lymphocytes (b): the effect of stimulation by phorbol myristate acetate in combination with ionomycin. The lymphocytes were stained directly
after isolation (dotted line histogram) or after 48h of culture with (dashed line histogram) or without mitogen (bold line histogram). Cells were stained
indirectly with SAF34 Mab and rabbit anti-mouse Ig PE-conjugated secondary antibody. Control ¼ secondary antibody alone (normal line histogram).
n ¼ 3.
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nevertheless the band intensities were weaker.
Modulation of PrPc Expression on Cultured
Lymphocytes
After incubation with enzymes to destroy the PrPc present
in the membrane, the cells isolated from the spleen or
mesenteric lymph nodes were treated in vitro with
tunicamycin which prevents lipid-carrier dependent
N-glycosylation of proteins. Concentrations of 1, 2 or
5mg/ml were used since higher doses (30 and 50mg/ml)
were shown by others to inhibit protein synthesis. The
efﬁciency of this treatment on lymphocytes was checked
by western blot with the SAF34 Mab which revealed only
the unglycosylated form of PrPc (29kDa—data not
shown). After treatment, PrPc was analyzed at the surface
of B and T cells by ﬂow cytometry. After an 18h
incubation with or without 5mg/ml of tunicamycin, PrPc
expression by spleen lymphocytes (Fig. 5) was equivalent
in both conditions.
DISCUSSION
Naturally occurring TSEs are probably transmitted by oral
or other peripheral routes of infection. Following
peripheral inoculation, the role of the immune cells was
clearly established using murine models of scrapie
neuroinvasion (Raeber et al., 1998) and in humans
suffering of vCJD (Hill et al., 1999). In fact, defects
affecting B-lymphocytes in mice, either at the level of the
differentiation or of the capacity of response, prevented
the development of clinical scrapie (Klein et al., 1997).
Race and collaborators (2000) debated the possibility of
hematogenous diffusion via leukocytes as a mechanism of
peripheral spread of infection to the brain. This situation
contrasts with the lack of infectivity in non-neural tissues
of natural and experimentally infected cattle, excepted in
the distal ileum at 6 months post-exposure (Wells et al.,
1994; Farquhar et al., 1996; Bradley, 1999). As PrPc
expression is required for susceptibility to TSEs (Bueler
et al., 1993; Weissman et al., 1994), this study was
designed to analyze characteristics of PrPc expression at
the surface of different bovine immune cells. The
regulation of PrP expression in different immune cell
populations would not only be important with regard to
the normal cellular function of PrPc but also have
relevance for the understanding of prion disease
pathogenesis.
We observed by cytoﬂuorimetry that, as previously
shown in humans (Cashman et al., 1990; Dodelet and
Cashman, 1998; Barclay et al., 1999; Antoine et al., 2000;
MacGregor et al., 2000; Barclay et al., 2002), PrP is
expressed in blood by B and T cells and monocytes but
not in signiﬁcant amounts on granulocytes. A study by
Du ¨rig et al. (2000) demonstrated that the human blood
monocytes have the same level of labeling at their
FIGURE 4 Western blot detection of PrPc with SAF34 MAb on brain
(Br) and splenic (S), tonsilar (To), mesenteric lymph nodes (MLN),
thymic (Th), blood (B) and Peyer’s patch (PP) lymphocytes directly after
isolation.
FIGURE 5 Comparative histograms of PrPc expression by
enzymatically treated splenic lymphocytes directly after a 18h
incubation with (dashed line histogram) or without tunicamycin
(bold line histogram). Cells were stained indirectly with SAF34 MAb
and rabbit anti-mouse Ig PE-conjugated secondary antibody.
Control ¼ secondary antibody alone (normal line histogram). n ¼ 3:
FIGURE 3 Comparative histograms of PrPc expression on
enzymatically treated splenic lymphocytes directly after isolation
(bold line histogram) or after six (dotted line histogram) or 18h
(dashed line histogram) of culture. Cells were stained indirectly with
SAF34 Mab and rabbit anti-mouse Ig PE-conjugated secondary antibody.
Control ¼ secondary antibody alone (normal line histogram). n ¼ 3:
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Our data show that bovine monocytes constitutively
express less PrPc than T cells and B cells do. On the basis
of analyses performed on immune cells prepared from
different lymphoid tissues from the same animal and
reproduced on six individuals, there was no evidence of
any link betweenthe lymphocyte subtype and the presence
or amount of surface PrP. We demonstrated that less
splenic cells are PrPc positive and that the staining is less
intense compared to that of other organs. One should
notice that for the spleen the data are globally the most
variable. This parallels the study of mature splenic B and
T cells in mice by Liu et al. (2001) or the study of ovine
tonsils and spleen by Moudjou et al. (2001). The
numerous splenic macrophages and granulocytes might
release enzymes able to detach surface PrPc.
In human samples, the intensity of the staining observed
for blood cells was high in comparison to that in the tonsils
(Antoine et al., 2000). This reduced intratissular PrPc
expression by human lymphocytes may result from a
reduced PrPc synthesis (downregulation) or may be due to
enzymatic cleavage when lymphocytes interact with the
extracellular matrix or with other cells (Jimenez-Huete
et al., 1998). We compared again the situation in human
with our experimental conditions on bovine samples.
We induced detachment of surface PrPc of living
lymphocytes with an enzymatic cocktail containing coll-
agenase-dispase-DNase after the data on the hydrolysis of
nascent PrPc from the cell surface of neuroblastoma (N2a)
cells with dispase (Borchelt et al., 1990;1992). We
demonstratedthat following invitroexposuretoproteases,
PrPc is reexpressed after a short-term incubation period
which correlates with the approximately 3 to 6h half-life
measured on hamster and chicken PrPc anchored in the
plasma membrane in neuroblastoma cells (Taraboulos
et al., 1992; Shyng et al., 1993).
We showed that bovine splenic and mesenteric lymph
node lymphocytes are able to express high quantities of
PrPc at their surface in culture conditions even without
stimulation. However, a treatment with PMA/ionomycin
upregulated PrPc expression at the surface of the activated
cells in vitro. Conﬂictual data were published as to the
effect of mitogenic stimulation: different works (Cashman
et al., 1990; Mabbott et al., 1997; Du ¨rig et al., 2000;
Li et al., 2001) suggest that PrPc expression on
haematopoietic cells correlates with their activation and
developmental status and that activation may play a role in
the propagation of TSEs. Nevertheless, cultivated human
tonsillar lymphocytes increase their PrPc expression
independently of the mitogenic activation (Antoine et al.,
2000). Furthermore, human blood cells express more PrPc
than within tissues but they are clearly less stimulated.
A unifying hypothesis may be that activation enhances
PrPc expression but that intercellular contacts
(i.e. enzymatic cleavage of surface PrPc) or intracellular
recycling induce the loss of surface PrPc.
We have previously detected PrPc with two antibodies
(SAF34 and 12F10) recognising N- and C-terminal
epitopes, respectively. Surprisingly, the results as to the
location of this protein within the germinal center and
more precisely on the FDCs depended on the antibody
used. We hypothesized that FDCs in bovine organs
express a particular form of PrPc. The N-terminal epitope
of PrPc might be absent (truncated form) in those samples,
or the sequence recognized by SAF34 MoAb might be
masked byinteractionwithothermolecules (Thielenetal.,
2001). In the present study, we could demonstrate that the
antibodies SAF34 and 12F10 react with PrPc of different
lymphocytes. This observation means that the PrPc
present at the surface of the lymphocytes is not particular
as to its N-terminal part. Moreover, the amount of PrPc
detected at the surface of the lymphocytes was
consistently less important with the 12F10 than with the
SAF34.
In order to reﬁne our analyses, we decided to reveal
the total content and the isoform distribution of PrP in
those cells by immunoblotting techniques. Since no
small fragments were detected in most samples, our
analyses conﬁrm that the lymphocytes do not follow the
particular PrPc pattern observed in FDCs. In light of
this result, we conﬁrm the hypothesis that the majority
of lymphocytic PrPc is not truncated. The presence of
only a diglycosylated band appears interesting.
Expressed by immune cells, this diglycosylated isoform
might perturb the conversion of PrPc into PrPres as
shown on other models by Capellari et al. (1999).
Anyway, different glycosylation patterns between neural
and immune tissues or within different parts of the
nervous system were already described in other species
(Li et al., 2001; Madec et al., 2000; Russelakis-Carneiro
et al., 2002).
Tunicamycin treatments, realized at a concentration
of 5mg/ml, evidenced a highly reduced synthesis of the
31–34kDa forms and an increase in the amount of the
29kDa band which corresponds to the unglycosylated
form, as reported in bovine spleen, kidney, liver and
adrenal gland by immunoblotting with the mAb BSPX-54
(Horiuchi et al., 1997). We could conclude from our ﬂow
cytometric data that in those conditions, N-glycosylation
is not necessary for the perfect folding and trafﬁcking of
the bovine PrPc to the cell surface. This is in accordance
with observations in other species (Petersen et al., 1996;
Lehmann and Harris, 1997).
Globally,ourresultssupportthenotionthatlymphocytes
might represent a possible target for prion transport and
replication in the bovine blood and lymphoid organs. As
revealedbytheincreaseofPrPcinbloodanditsdecreasein
tissues during lymphocyte recirculation, we can conclude
on the basis of our observations on bovine and human
(Antoineetal.,2000)thatintissues,enzymaticcleavageof
surface PrPc may explain its loss. Small differences in
the surface distribution of electrostatic charges of bovine
PrP, compared to that of the human prion protein
(Lopez Garcia et al., 2000), or interspecies variation
of the immune system within mammals (Lascelles and
McDowell, 1974; Gallo and Wong-Staal, 1982)
F. ME ´LOT et al. 250could explain the small discrepancies between previous
results on human and the present study. Additional factors
are thus required to explain the lack of infectivity of the
bovine immune cells; the glycosylation state could be one
ofthem.Thekeyofthisnon-infectiouscharactermightalso
reside in the interaction of PrPc with other molecules.
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